||| Menü 
Firmenveranstaltungen, Neuemissionen

Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

Fusionen, Übernahmen

Personal, Belegschaft, Meldungen zu Produkten


Bankleitzahlen - online.de

Novartis survey shows psoriasis patients want treatment effect beyond clear skin

Novartis International AG /
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

* New patient preference survey confirms that patients value clear skin the
most, but expect additional benefits from their treatment, such as proven
long-term efficacy and safety data and no injection site reactions[1]

* A separate ranking incorporating additional characteristics showed that
effectiveness in treating multiple manifestations of psoriatic disease was
also important[1]

* The number of injections per dose and injection frequency were least
important to patients according to the ranking analysis[1]

Basel, September 12, 2018 - Novartis, a leader in immuno-dermatology, announced
today new data from a patient preference survey showing psoriasis patients want
their treatment to go beyond just clear skin and safety. This study of 300
psoriasis patients is being presented during a poster session at the 27(th)
European Academy of Dermatology and Venereology (EADV) Congress in Paris,

Results confirmed that clear skin is the most preferred treatment attribute,
which is consistent with previous patient preference surveys in psoriasis[2]-
[5]. Results also show patients expect additional benefits from their treatment
that are not traditionally assessed in patient surveys, including the number of
years of proven efficacy and safety data in large clinical trials and no
injection site reactions[1].

In a separate ranking incorporating additional characteristics, patients ranked
the effectiveness in treating multiple manifestations of psoriatic disease
(including PsA, nail, palmoplantar and scalp), and complete symptom relief, as
being important, after risk of side effects and clear skin (including time to
achieve clear skin)[1]. Least important were the number of injections per dose
and injection frequency[1].

"It's relevant to understand from psoriasis patients which additional benefits
from their treatment they want besides clear skin and safety," said Professor
Matthias Augustin, Director Institute of Health Care Research in Dermatology and
Nursing, University of Hamburg. "From the findings of this survey, consistent
and sustained long term efficacy and safety from large clinical studies, no pain
at injection site or efficacy in all manifestations of psoriatic disease could
be influential when choosing a treatment for moderate-to-severe psoriasis."

"The survey will help Novartis and dermatologists better understand patient
preference in selecting psoriatic disease treatment options," stated Sam Khalil,
PhD, Head Worldwide Medical Affairs, Immunology, Hepatology and Dermatology. "It
supports Novartis goal of leadership in immuno-dermatology and our commitment to
improving patient care. Reimagining medicine for patients, starts by listening
to what patients truly want and need."

Psoriatic disease is complex and multifaceted. Up to 40% of psoriasis patients
may develop PsA[6]. In the long term, up to 90% of psoriasis patients may also
develop nail psoriasis, palmoplantar psoriasis (of the palms of the hands and
soles of the feet), or scalp psoriasis[8]-[10]. These manifestations are
associated with a greater burden on patients' life.

According to the American Academy of Dermatology's guidelines, psoriasis
treatments should be tailored to the patient's situation and preference[11]. A
greater understanding of patients' preferences for moderate-to-severe psoriasis
treatment is central to improving models of shared patient-doctor decision
making. These results provide additional insight into the patients' perspective
of the psoriasis treatment options available.

About the patient preference study[1]
The aim of the patient preference study was to quantify the relative patient
preferences for five selected attributes that may differentiate among biologic
treatments for moderate-to-severe plaque psoriasis. The data was collated from
an online discrete choice experiment (DCE) survey from 300 US respondents with a
self-reported physician diagnosis of moderate-to-severe psoriasis. Levels of
attributes were based on existing clinical information for current biologic
treatments of moderate-to-severe plaque psoriasis.

In addition, patients ranked the importance of an expanded list of treatment
attributes, which included the five DCE attributes plus five additional
psoriasis-relevant treatment attributes, in a separate and exploratory series of
direct questions.

About psoriasis
Psoriasis is a distressing and painful autoimmune disease that affects more than
125 million people worldwide[7]. It is a debilitating condition associated with
a significant emotional and physical daily burden. In the long-term, psoriasis
can also lead to other conditions, such as diabetes, heart disease, depression
and psoriatic arthritis (PsA) - which up to 40% of patients with psoriasis may

Plaque psoriasis is the most common form of the disease and appears as raised,
red skin patches covered with a silvery white build-up of dead cells. Most
patients with psoriasis will also develop difficult-to-treat forms of the
disease which appear on the scalp, nails, palms of the hands or soles of the
feet and are associated with further pain, decreased mobility and functional

About Novartis Immunology & Dermatology
Novartis is a global leader in Immunology & Dermatology. We are dedicated to
transforming the lives of people living with immunologic diseases, focusing on
immunodermatology, rheumatology and specialty liver diseases. Our Immunology &
Dermatology pipeline includes multiple compounds in liver disease and other
immunological areas where high unmet medical needs exist.

This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "potential," "can,"
"will," "plan," "expect," "anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by express or
implied discussions regarding potential marketing approvals, new indications or
labeling for the investigational or approved products described in this press
release, or regarding potential future revenues from such products. You should
not place undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that the
investigational or approved products described in this press release will be
submitted or approved for sale or for any additional indications or labeling in
any market, or at any particular time. Nor can there be any guarantee that such
products will be commercially successful in the future. In particular, our
expectations regarding such products could be affected by, among other things,
the uncertainties inherent in research and development, including clinical trial
results and additional analysis of existing clinical data; regulatory actions or
delays or government regulation generally; global trends toward health care cost
containment, including government, payor and general public pricing and
reimbursement pressures; our ability to obtain or maintain proprietary
intellectual property protection; the particular prescribing preferences of
physicians and patients; general political and economic conditions; safety,
quality or manufacturing issues; potential or actual data security and data
privacy breaches, or disruptions of our information technology systems, and
other risks and factors referred to in Novartis AG's current Form 20-F on file
with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2017, the Group achieved
net sales of USD 49.1 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
125,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit

Novartis is on Twitter. Sign up to follow @Novartis at
For Novartis multimedia content, please visit www.novartis.com/news/media-
For questions about the site or required registration, please contact

[1]    Feldman S, et al. Exploring Patient Preferences for the Treatment of
Moderate to Severe Psoriasis: a Discrete Choice Experiment Study in the US,
Abstract presented at EADV, 2018
[2]    Niedhardt K. Patient-Relevant Endpoints In Psoriasis - A Literature
Review Of Patient Preference Studies. Value Health. 2016;19(7):a571
[3]    Kauf T L , et al. Psoriasis patients' willingness to accept side-effect
risks for improved treatment efficacy. Journal of Dermatological Treatment.
[4]    Feldman S, et al. Journal of Health Economics and Outcomes Research.
[5]    Gonzalez J M, et al. Comparing preferences for outcomes of psoriasis
treatments among patients and dermatologists in the UK: results from a discrete-
choice experiment. British Journal of Dermatology. 2017;176(3) 777-785
[6]    Mease P J, et al. Managing patients with psoriatic disease: the diagnosis
and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
Drugs 2014;74:423-41.
[7]    International Federation of Psoriasis Associations (IFPA) World Psoriasis
Day website. "About Psoriasis." Available at:
http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Last accessed January
[8]    Baran R. The burden of nail psoriasis: an introduction. Dermatol.
2010:221 Suppl 1:1-5.
[9]    Kumar B, et al. Palmoplantar lesions in psoriasis: a study of 3065
patients. Acta Dermatol Venereol. 2002;82:192-5.
[10]  Zampieron A, et al. Quality of life in patients with scalp psoriasis. G
Ital Dermatol Venereol. 2015 Jun;150(3):309-16
[11]  Menter, et al. Journal of the American Academy of Dermatology.
2008; 58(5):826-50
[12]  Chung J, et al. Palmoplantar psoriasis is associated with greater
impairment of health-related quality of life compared with moderate to severe
plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623-32.

# # #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Eric Althoff Friedrich von Heyl
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8984 (direct)
+41 79 593 4202 (mobile) +41 79 749 0286 (mobile)
eric.althoff@novartis.com friedrich.vonheyl@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF):

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire

 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Sehr gut

Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.078 Sekunden